KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Sep 10, 2025, 7:25 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Despite projected losses, strong analyst ratings suggest potential recovery. Historical patterns show bullish sentiment can support stock prices even with losses.
AI summary
What happened, with direct paths to the underlying reporting
KALV to report Q1 earnings on Sept. 11 with expected losses. Projected revenue for Q1 is $2.09 million. Company's shares recently fell 2.2% to $15.61. Analysts maintain bullish ratings with price targets up to $28. Orphan designation for Sebetralstat maintained in the EU.
KALV to report Q1 earnings on Sept. 11 with expected losses.
Projected revenue for Q1 is $2.09 million.
Company's shares recently fell 2.2% to $15.61.
Analysts maintain bullish ratings with price targets up to $28.
Orphan designation for Sebetralstat maintained in the EU.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Chiesi Group has announced its acquisition of KalVista Pharmaceuticals for $1.9 billion in cash, equating to $14.75 per share. This deal, expected to close in Q1 2024, positions C…
KALV's Ekterly shows strong commercial momentum and prescriber growth. Preliminary Q4 revenue reached $35 million, with $49 million for FY 2025. Prescription refills are now the m…